Radio-and chemo-sensitizing effects of a new sensitizer, metronidazol amino acidum natrium (CMNa), were studied by the methods of cell surviving fraction (in viiro), tumor growth delay (in vivo) and clinical observati...Radio-and chemo-sensitizing effects of a new sensitizer, metronidazol amino acidum natrium (CMNa), were studied by the methods of cell surviving fraction (in viiro), tumor growth delay (in vivo) and clinical observation. When the hypoxic V79 cells were exposed to γ-ray and CMNa, the cell surviving fraction decreased markedly as compared with radiation alone. The sensitizer enhancement ratio (SER) value was 1. 26-2. 32. When the mice bearing Lewis . B16 melanoma or EMT6 tumors were treated with single dose or fractionated radiation (with or without CMNa) or with antitumor agents (with or without CMNa) the tumor increasing velocity slowed down and the days of tumor growth delay increased significantly when CMNa was given simultaneously.In 96 cases of lung cancer and 80 cases of esophageal cancer patients treated with routine chemotherapy or radiotherapy combined with CMNa, the percentage of CR+PR increased significantly. These results showed that CMNa may be an effective radio- and chemo-sensitizer.展开更多
Objective: The aim of this study was to explore whether low dose Glycididazolum natrium (CMNa) used during intervention for advanced non-small cell lung cancer (NSCLC) patients can enhance chemo-sensitivity and to eva...Objective: The aim of this study was to explore whether low dose Glycididazolum natrium (CMNa) used during intervention for advanced non-small cell lung cancer (NSCLC) patients can enhance chemo-sensitivity and to evaluate its clinical value. Methods: One hundred and twenty cases of advanced NSCLC patients treated by intervention chemotherapy through bronchial artery, collected from 2005 to 2008, were randomly divided into two groups: experimental group (group A), 75 cases, 0.25g CMNa was administered before chemical drugs; control group (group B), 45 cases, chemical drugs only. There were no differences of operation procedures and chemo-regimens between the two groups. After intervention, imaging and clinical data were collected periodically and were processed statistically. Results: The effective rate of group A was higher than that of group B (P < 0.05). Responsive rate (RR) in group A was 61% and it was 38% in group B. There were some side effects in the two groups but there were no statistical differences. Conclusion: Low dose CMNa can enhance chemosensitivity during intervention, which can elevate chemotherapeutical effects on NSCLC. Meanwhile the side effects were not increased. This method is worthy of popularizing.展开更多
文摘Radio-and chemo-sensitizing effects of a new sensitizer, metronidazol amino acidum natrium (CMNa), were studied by the methods of cell surviving fraction (in viiro), tumor growth delay (in vivo) and clinical observation. When the hypoxic V79 cells were exposed to γ-ray and CMNa, the cell surviving fraction decreased markedly as compared with radiation alone. The sensitizer enhancement ratio (SER) value was 1. 26-2. 32. When the mice bearing Lewis . B16 melanoma or EMT6 tumors were treated with single dose or fractionated radiation (with or without CMNa) or with antitumor agents (with or without CMNa) the tumor increasing velocity slowed down and the days of tumor growth delay increased significantly when CMNa was given simultaneously.In 96 cases of lung cancer and 80 cases of esophageal cancer patients treated with routine chemotherapy or radiotherapy combined with CMNa, the percentage of CR+PR increased significantly. These results showed that CMNa may be an effective radio- and chemo-sensitizer.
文摘Objective: The aim of this study was to explore whether low dose Glycididazolum natrium (CMNa) used during intervention for advanced non-small cell lung cancer (NSCLC) patients can enhance chemo-sensitivity and to evaluate its clinical value. Methods: One hundred and twenty cases of advanced NSCLC patients treated by intervention chemotherapy through bronchial artery, collected from 2005 to 2008, were randomly divided into two groups: experimental group (group A), 75 cases, 0.25g CMNa was administered before chemical drugs; control group (group B), 45 cases, chemical drugs only. There were no differences of operation procedures and chemo-regimens between the two groups. After intervention, imaging and clinical data were collected periodically and were processed statistically. Results: The effective rate of group A was higher than that of group B (P < 0.05). Responsive rate (RR) in group A was 61% and it was 38% in group B. There were some side effects in the two groups but there were no statistical differences. Conclusion: Low dose CMNa can enhance chemosensitivity during intervention, which can elevate chemotherapeutical effects on NSCLC. Meanwhile the side effects were not increased. This method is worthy of popularizing.
